SOST and Alzheimer disease: Given the fact that SOST is a Wnt signaling inhibitor and its levels in the blood are elevated with age, we hypothesize that plasma SOST is associated with early AD pathological change, i.e., cerebral Aβ deposition, and could be a potential predictive blood biomarker for AD in individuals “at risk”.